CI 1033

DRUG2 trials

Sponsors

Pfizer

Conditions

Carcinoma, Non-Small Cell LungLung Neoplasms

Phase 1

PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients

CompletedNCT00174356

PfizerCarcinoma, Non-Small Cell Lung

Start: 2002-12-31End: 2005-10-31Target: 39Updated: 2006-11-08

Phase 2

A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer

CompletedNCT00050830

PfizerLung Neoplasms

Start: 2003-01-31End: 2005-11-30Target: 163Updated: 2006-11-08